Abstract
Objective To determine the predictive efficacy of measuring fibroblast growth factor 23 (HPDR2) in postmenopausal individuals with osteoporosis, tartrate-resistant acid phosphatase 5b (TRACP-5b), and serum macrophage inflammatory protein-1 β (CCL4) for fractures.
Methods The osteoporosis group consisted of 242 postmenopausal individuals with osteoporosis who were admitted to the hospital between January 2023 and January 2025. There were two groups of patients: 108 patients with fractures and 134 patients without. The decreased bone mass group (164 patients) and the control group (130 patients) were composed of postmenopausal women who were diagnosed with decreased bone mass and normal bone mass in the hospital during the same time period. The levels of serum CCL4, TRACP-5b and HPDR2 in each group were compared. The predictive value of serum CCL4, TRACP-5b, and HPDR2 detection for fractures in postmenopausal patients with osteoporosis was assessed using univariate and multivariate analysis on the influencing factors of fractures in patients with osteoporosis. The relationships between the levels of serum CCL4, TRACP-5b and HPDR2 and the severity of fractures were analyzed.
Results The levels of serum CCL4, TRACP-5b and HPDR2 in the osteoporosis group were significantly greater than those in the decreased bone mass group and the control group (P<0.01), and the reduced bone mass group's serum CCL4, TRACP-5b, and HPDR2 levels were considerably higher than the control group's (P<0.01). The fracture group had significantly greater serum levels of HPDR2, TRACP-5b, and CCL4 than the nonfracture group (P<0.01). Multivariate analysis revealed that serum CCL4>719.75 pg/mL, TRACP-5b>6.90 U/L and HPDR2>247.35 pg/mL were risk factors for fractures in postmenopausal patients with osteoporosis (P<0.01). The levels of serum CCL4, TRACP-5b and HPDR2 are highly effective at predicting fractures in patients with osteoporosis (P<0.01). The combined detection sensitivity of the three indicators was 90.0%, the specificity was 89.7%, and the area under the curve (AUC) was 0.949. The AUC was significantly greater than that of CCL4 (Z=3. 415, P<0.01), TRACP-5b (Z=3.814, P<0.01), and HPDR2 (Z=3.986, P<0.01) were detected as individual indicators. However, the AUC of each individual indicator did not change statistically significantly (P>0.05).
Conclusion Serum CCL4, TRACP-5b and HPDR2 are involved in the occurrence and development of postmenopausal osteoporosis. The detection of their levels has high value in predicting fractures in postmenopausal osteoporosis patients.
Keywords
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.